by Truveta staff | Aug 6, 2026 | Research
Authors: Hannah A Burkhardt, PhD ⊕Truveta, Inc, Bellevue, WA, Sarah J Blach, MHS ⊕Truveta, Inc, Bellevue, WA, Srinivasa R Burugapalli, MS ⊕Truveta, Inc, Bellevue, WA, Brianna M Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Ryley Martin, BS ⊕Truveta, Inc, Bellevue, WA,...
by Truveta Research | Jul 30, 2026 | Featured research, Research
During July 2026, the rate of cyclosporiasis diagnosis reached 10.5 per 100,000 people with a healthcare encounter, more than 11-fold higher than the average July rate observed between 2018 and 2025 (0.9 per 100,000). More than 1 in 5 patients with a cyclosporiasis...
by Truveta staff | Jul 29, 2026 | Research
Authors: Swapna Abhyankay, MD ⊕Truveta, Inc, Bellevue, WA, Rajesh M Rao, MS ⊕Truveta, Inc, Bellevue, WA, Mehraveh Salehi, PhD ⊕Truveta, Inc, Bellevue, WA, Jennifer J Liang, MD ⊕Truveta, Inc, Bellevue, WA, Jamalynne Deckard, MS ⊕Truveta, Inc, Bellevue, WA, Sujatha...
by Truveta Research | Jul 21, 2026 | Research
Authors: Patrica J Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Jay B Lusk, MD, MBA ⊕University of North Caroline-Chapel Hill, Chapel Hill, NC, Hemalkumar Mehta, PhD ⊕Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Joseph F Levy, PhD ⊕Johns...
by Truveta Research | Jul 20, 2026 | Research
More than 8% of all prescriptions in June 2026 were for GLP-1 RAs, increasing slightly (+5.6%) since March 2026. Tirzepatide remained the leading anti-obesity medication (AOM) and anti-diabetic medication (ADM) by prescription volume and showed the largest increase in...
by Truveta Research | Jul 20, 2026 | Research
More than 2 in 5 patients (40.3%) initiating oral orforglipron (Foundayo pill) had no prior evidence of GLP-1-based medication use, suggesting early uptake extends beyond patients already receiving injectable therapies. Among patients with prior GLP-1-based medication...
